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aBstraCt
Preservatives are added to eye drops in order to increase the shelf life of these medications. However, these preserva-
tives may have some adverse effects on the eye. Various adverse effects of preserved ocular medications have been po-
inted out by multiple investigators time and again. These preservatives are added to most ocular medicines in today’s 
practice. Given the fact that many patients need to instill these medications for long periods, such as anti-glaucoma 
medications, the adverse effects of these preservatives need to be taken into account. Benzalkonium chloride is the 
most widely used preservative in ocular medications and has a lot of adverse effects. Various other alternative pre-
servatives have been developed in more recent times. In this article, a broad overview regarding various researches 
exploring the different adverse effects of these preservatives has been compiled and presented comparatively.
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introduCtion
Preservatives are added to topical ophthalmic 
drug solutions in order to prevent contamination 
with pathogenic organisms. In other words, preserv-
atives increase the shelf life of ocular medications.
Preservatives used in ocular medications are cat-
egorized into two broad categories: detergents and 
oxidizing agents. More recently, ionic-buffer system 
preservatives have been introduced.
Detergents exert their effect by disrupting the 
cell membrane’s lipid layer leading to cell mem-
brane instability and extrusion of bacterial cell con-
tents. Benzalkonium chloride (BAK), polyquater-
nium-1 (Polyquad), and cetrimonium are examples 
of detergent preservatives [1].
Oxidizing preservatives are considered sec-
ond-generation ocular preservatives that exert 
their effect by penetrating the cell and altering 
the DNA, protein, and lipid component of the 
bacterial cell [2]. Oxidizing preservatives are con-
sidered to be less harmful to the ocular surface 
cells. Noecker et al. has reported the preservative 
stabilized oxychloro complex (SOC) (Purite) to 
be less toxic to the cornea than BAK [3]. Sodium 
perborate and SOC are examples of oxidizing pre-
servatives.
Ionic-buffer systems are the latest addition in 
the classification of preservatives. This class of pre-
servatives acts similarly to the oxidizing preserva-
tives. SofZia (Alcon, TX, USA) is an example of 
this class and is constituted by zinc, sorbitol, boric 
acid, and propylene glycol. This has both antibacte-
rial and antifungal qualities. Moreover, on being 
exposed to cations, such as those in the tear film, the 
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substance becomes inactive and thus is less cytotoxic 
to the ocular surface [4]. 
Of the many preservatives, BAK is the most 
commonly used preservative [2]. BAK is a qua-
ternary ammonium compound that exerts its mi-
crobicidal action by disrupting the microorgan-
isms’ cell membranes. First introduced way back 
in 1910 as a germicide, it soon found a wide array 
of uses. By 1940 it was being used in toilet prod-
ucts such as: aftershave, mouthwash, handwashes, 
laundry detergents, softeners for textiles, deodor-
ants, hair products, sanitizers, in medical products 
like nasal sprays, spermicides, disinfectants for 
surgical instruments, burn and ulcer treatment, 
preoperative skin disinfectants and so on. BAK was 
initially used in solutions for preserving hard con-
tact lenses, which was perhaps the first use of BAK 
in ophthalmology. BAK is undoubtedly the most 
frequently used preservative in topical eye drops 
today, used in concentration ranges from 0.004% 
to 0.02%. BAK is used so frequently as a pre-
servative because of its extreme efficacy in tackling 
microbial contamination of eye drops and its capa-
bility to disrupt cell–cell junctions in the corneal 
epithelium, thus allowing drug particles of topical 
eye drops to enter the anterior chamber. Besides, 
on account of being out there for such a long time, 
BAK is very familiar to those who are formulat-
ing topical ophthalmic drug solutions. Hence is 
the most commonly used preservative in eye drop 
formulations [2].
However, there have been concerns regarding 
the safety profile of BAK, especially considering its 
adverse effects on the ocular surface.
Literature review method
A thorough literature search was made using key-
words “ocular preservatives”, “benzalkonium chlo-
ride”, “adverse effects”, “ocular surface tolerance”, 
“adverse effects”, “ocular adverse effects”, “ocular 
surface health”, in PubMed, Google Scholar and 
Directory of Open Access Journals. All the relevant 
articles discussing adverse effects of preservatives in 
eye drops, comparing two or more preservatives in 
terms of adverse effects or ocular tolerance, were 
shortlisted. The references from these articles were 
also looked into, and the relevant ones were added 
to the list. The summaries of these articles were 
noted down and later categorized. Some repetitive 
articles were discarded.
BaK and oCuLar surfaCe
Most of the literature and peer-reviewed articles 
on preservative toxicity focuses on BAK as it is the 
most commonly used preservative and perhaps is 
the most toxic of all. BAK can accumulate in ocular 
tissues and induce changes in the conjunctiva and 
cornea which may manifest as an ocular surface dis-
ease (OSD). OSD occurrence is reportedly as high 
as thrice that of the general population in patients 
on chronic anti-glaucoma medications [5].
Following are the reported adverse effects of 
BAK on different ocular structures.
tear film
The detergent action of BAK affects the lipid 
layer and affects tear film stability decreasing the 
tear break up time (BUT). One randomized crosso-
ver study compared topical carteolol with and with-
out BAK. It was evident that the BAK-containing 
solution significantly decreased the tear break-up 
time compared to baseline values in healthy volun-
teers [6]. In another randomized prospective trial by 
Aihara et al., switching from BAK preserved latano-
prost to SofZia preserved travoprost significantly 
improved the tear break-up time when the switch-
ing was done after three months of therapy with the 
former, while there was no significant change in tear 
break-up time in those who had continued therapy 
with BAK preserved latanoprost [7]. In another 
study, tear break-up time was reported to be signifi-
cantly lower from baseline following three months 
of treatment with BAK preserved travoprost [5]. 
Crichton et al. have reported tear film instability af-
ter treatment for 12 weeks with different preserved 
prostaglandin analogues; no difference in BUT was 
reported across the various drug groups though [8]. 
Rossi et al. have reported that dry eye disease occurs 
significantly more frequently in glaucoma patients 
on topical medications [9]. Uusitalo et al. conducted 
a study in which patients with ocular signs and 
symptoms of OSD were treated with BAK-pre-
served latanoprost eye drops (containing 0.02% 
benzalkonium chloride). They then were switched 
to receive preservative-free tafluprost and followed 
up for 12 weeks. The tear break-up time reportedly 
improved significantly from 4.5 ± 2.5 seconds at 
baseline to 7.8 ± 4.9 seconds at 12 weeks, which 
was statistically significant. Schirmer test scores im-
proved too, and the results were statistically signifi-
cant at six weeks. The percentage of patients who 
had abnormal Schirmer test result at baseline had 
ophthaLmoLogy JournaL 2021, Vol. 6
46 www.journals.viamedica.pl/ophthalmology_journal
decreased from 71.5% to 61.5% at six weeks and to 
59.4% at 12 weeks [10]. 
The author of the present article had evaluated 
the long-term effects of anti-glaucoma medica-
tions with and without BAK on tear film stability. 
In this study, newly diagnosed glaucoma patients 
were started on either preservative-free travoprost 
0.004% or Latanoprost 0.005% preserved with 
0.02% BAK. After one year of follow-up, a more 
significant number of patients instilling BAK-pre-
served drops had tear film instability compared to 
those instilling preservative-free drops and con-
trols [11].
Conjunctiva
In an in vitro study demonstrating the effects of 
preservative-free and preserved prostaglandin ana-
logues on cultured human conjunctival fibroblasts, 
it was seen that BAK induced apoptosis caused cell 
shrinkage and reduced cell viability in a dose-de-
pendent fashion [12]. In another in vitro study, 
latanoprost with BAK, travoprost with BAK, and 
BAK alone had significant cytotoxic effects on hu-
man conjunctiva-derived cells and were associated 
with apoptosis [13]. In another study, the toxicity 
on cultured human corneal and conjunctival cells 
related to the prostaglandin analogs latanoprost, 
tafluprost, and travoprost preserved with BAK was 
similar to the toxicity observed in their respective 
BAK concentrations. It proved the fact that the 
drugs themselves are not toxic to the conjunctival 
cells. In that same study, it SofZia preserved tra-
voprost, and polyquad containing travoprost had 
significantly greater corneal and conjunctival cell 
survival [14]. In an in vitro experiment for study-
ing the effects of BAK on the human conjunctival 
cell line, BAK induced cell growth arrest and death 
even at a concentration of 0.0001%. BAK-induced 
cell death was also dose-dependent — cells died 
by necrosis at higher concentrations of BAK and 
by apoptosis at lower concentrations of BAK [15]. 
Sherwood et al. reported an increased number of 
macrophages, lymphocytes, mast cells, and fibro-
blasts in the conjunctiva and Tenon’s capsule and 
a significant decrease in the number of epithelial 
goblet cells in conjunctival biopsies of patients in-
stilling anti-glaucoma medications for at least one 
year (mean 7.7 years) [16]. It has been shown that 
the success rate of trabeculectomies is higher in 
patients who had instilled topical anti-glaucoma 
medications only for two weeks compared to those 
who had instilled them for at least one year [17]. 
This perhaps is due to anti-glaucoma medications’ 
effects on the conjunctival cells and fibroblasts, 
as demonstrated in the in vitro studies [18, 19]. 
However, in these studies, it has not been clarified 
whether the effects was caused by the medication 
itself, the preservatives, or both. Mietz et al. reported 
a slight increase in antibodies against type IV colla-
gen, a-smooth muscle actin, and subepithelial col-
lagen thickness in rabbit eyes treated with medica-
tions with preservatives while these effects were not 
seen in eyes treated with medications alone [20]. 
Uusitalo et al. studied HLA-DR positive conjunc-
tival epithelial cells and MUC5AC expressing gob-
let cells in impression cytology specimens. Authors 
reported significant changes toward normalization 
during treatment with preservative-free tafluprost as 
opposed to with BAK-preserved latanoprost. These 
results suggest that preservative-free tafluprost has 
less harmful effects on the conjunctiva [10]. In or-
der to limit adverse effects on the eye, it’s essential 
to establish if the cytological changes are chiefly 
due to the preservatives’ influence or the medica-
tions themselves.
Cornea
Burstein demonstrated cell lifting, peeling of 
epithelial cells, and exposure of underlying cell lay-
ers in rabbit and cat corneas when treated with 
0.01% and 0.0075% BAK; the effect was much 
less significant with lower concentrations of BAK 
[21]. In an in vivo study, Kim et al. examined the 
effects of prostaglandin analogues with and with-
out BAK on mouse ocular surface. In this study, 
severe punctuate epithelial keratitis was reported 
in eyes treated with BAK-containing drops. Also, 
surface desquamation, loss of cell borders, anisocy-
tosis, and stromal shrinkage were noted in corneas 
treated with BAK-containing drops. Additionally, 
the corneas treated with BAK also showed decreased 
cell viability markers, increased apoptosis-inducing 
signals, and increased inflammatory cytokines [22]. 
Meda et al. reported that stopping chronic topical 
prostaglandin analogue treatment significantly in-
creases corneal hysteresis, corneal resistance factor, 
and central corneal thickness, and reinitiation of 
therapy reverted these changes [23].
preservatives and oCuLar toLeranCe
Uusitalo et al. presented results of two independ-
ent clinical phase IIIb studies [10, 24]. The stud-
ies’ design was identical. Patients who developed 
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signs and symptoms of OCD while on treatment 
with latanoprost containing 0.02% benzalkonium 
chloride were switched to receive preservative-free 
tafluprost and were evaluated for 12 weeks. Dur-
ing follow-up after switching to preservative-free 
tafluprost, a statistically significant shift toward less 
severe symptoms such as burning, stinging, foreign 
body sensation, itching, and dry eye sensation, was 
seen after six weeks. A continued improvement was 
observed starting from 6 to 12 weeks. At 12-weeks, 
among symptomatic at baseline patients, the propor-
tion of patients treated with preservative-free taflu-
prost was only around one-third of patients using 
latanoprost. Likewise, there was a reported decrease 
in the frequency distribution of ocular signs after 
the switch. The severity of conjunctival hyperemia 
reportedly got reduced to half over the 12-week 
treatment period. The incidence of hyperemia also 
got reduced.
Regarding drop discomfort, there was a signifi-
cant increase in the percentage of patients who had 
reported no drop discomfort after 12 weeks of treat-
ment with preservative-free tafluprost. Furthermore, 
most of the patients preferred preservative-free 
tafluprost as opposed to preserved latanoprost. Up 
to 72% of the patients favored tafluprost, while only 
6% opted for latanoprost in terms of medication 
preference [25].
Shedden et al. obtained opposite results. The 
authors performed a double-masked study in which 
261 patients were having either primary open-angle 
glaucoma (POAG) or ocular hypertension (OHT). 
Patients were randomized to receive either a pre-
servative-free preparation of dorzolamide/timolol 
combination or one containing 0.0075% BAK. 
The authors reported both the formulations to be 
well tolerated. There was no statistical difference 
between the two formulations in terms of adverse 
effects clinically. A similar proportion of patients in 
each group had punctate epithelial erosions. Three 
patients in the BAK group had to discontinue their 
medication due to adverse effects, while four pa-
tients in the preservative-free group discontinued 
their treatment due to it’s side effects [26].
Sezgin Akçay et al. carried out a prospective study 
comparing the toxic effect of polyquaternium- (PQ) 
and benzalkonium chloride- (BAK) preserved tra-
voprost on the ocular surface. On the basis of im-
pression cytological examination, ocular surface 
disease index (OSDI) questionnaire, Schirmer test, 
and tear film break up time (TBUT) measurements, 
the authors made their observations. Based on their 
observations, the authors concluded that PQ-pre-
served travoprost was safer and better-tolerated than 
BAK-preserved travoprost; also, PQ-preserved travo-
prost reportedly provided better ocular surface com-
fort and hence led to better patient experience [27].
Goldberg et al. performed a double-masked 
randomized controlled trial comparing bimato-
prost 0.03%/timolol 0.5% combination with and 
without BAK (0.005%) in 561 patients with either 
POAG or OHT. Adverse effects were reported in an 
equal percentage of patients in the preservative-free 
and BAK groups (28.8% and 28.7%, respectively). 
Conjunctival hyperemia was the most common ad-
verse effect. No statistically significant difference 
was seen between the two groups in terms of con-
junctival hyperemia, itching, dry eye, pain, eyelash 
growth, and lid erythema [28]. 
Crichton et al. conducted a randomized, mul-
ticenter study with the investigator’s blinding to 
compare the ocular surface tolerability of 0.02% 
BAK-preserved bimatoprost, 0.02% BAK-preserved 
latanoprost, and SofZia-preserved travoprost in 
patients with POAG or OHT. In this study all 
newly diagnosed patients were put on latanoprost 
monotherapy for 30 days. At the end of that pe-
riod, they were randomized into three groups with 
a 1:1:1 ratio: bimatoprost (preserved with BAK) 
group; latanoprost (preserved with BAK) group; 
travoprost (SofZia-preserved) group.
The authors reported no statistically significant 
differences in conjunctival hyperemia, corneal stain-
ing, or tear-breakup time among the three groups, 
not at baseline or at 12 weeks follow-up. Also, the 
three treatments were well tolerated by the patients, 
and adverse events were sparse and comparable 
across the groups [8]. 
In the previously cited study by Aihara et al., 
changing the treatment from BAK-preserved latan-
oprost to SofZia-preserved travoprost after three 
months of treatment with the former did not cause 
a significant change in the frequency of keratocon-
junctival epitheliopathy in patients who continued 
with BAK-preserved latanoprost. However, a sig-
nificant decrease was observed in patients who were 
switched to SofZia-preserved travoprost. Regard-
ing the frequency of superficial punctuate keratitis 
(SPK), the authors found that the frequency of SPK 
improved significantly in the group that switched 
from BAK-preserved latanoprost to SofZia-pre-
served travoprost [7].
Ranno et al. compared the effects of tafluprost 
with other BAK-preserved prostaglandin analogs in 
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a prospective study. The analysis of OCD showed 
no statistical difference between BAK-preserved 
latanoprost and unpreserved tafluprost and between 
BAK-preserved travoprost and unpreserved taflu-
prost. However, BAK-preserved bimatoprost induced 
a slightly higher conjunctival hyperemia and punctu-
ated keratitis than unpreserved tafluprost [29].
Hamacher et al. performed a randomized cross-
over trial evaluating the pharmacodynamics and 
safety of preserved and preservative-free tafluprost 
eye drops. In this study, both the preserved and 
non-preserved formulations were well-tolerated by 
the patients, and ocular adverse effects were mild. 
No serious adverse effects were reported. For the 
preservative-free formulation, slightly higher ocular 
adverse events were reported as compared to the 
preserved formulation. The most frequently report-
ed adverse event in both groups was conjunctival 
hyperemia. The incidence of conjunctival hyper-
emia was reported more frequently by patients using 
the preservative-free tafluprost as opposed to the 
preserved formulation [30]. 
In another similar study in healthy volunteers, 
comparable incidences of conjunctival hyperemia 
have been reported for both the preservative-free 
and the preserved formulations. However, the hy-
peremia was mostly of moderate severity with pre-
served tafluprost, while with preservative-free taflu-
prost, it was of mild severity [31].
In a multicenter cross-sectional epidemiologic 
survey in four European countries, Jaenen et al. 
compared the prevalence of side effects between 
eyedrops with or without preservatives regarding 
subjective symptoms and objective signs in POAG 
patients. Authors reported that all the studied symp-
toms and signs like pain or discomfort during instil-
lation, stinging, foreign body sensation, and dry eye 
sensation were more significant in patients using 
eye drops with preservatives than patients using pre-
servative-free drops. There was a significant decrease 
in the ocular signs and symptoms after switching 
from the preserved eye drops to preservative-free 
ones [32].
Rossi et al. reported that the presence of dry 
eye disease in topically treated glaucoma patients 
bears a negative influence on the patients’ quality 
of life [33].
preservatives and drug effiCaCy
In the randomized crossover trial conducted 
by Hamacher et al., there was a similar reduction 
in intraocular pressure (IOP) (more than 5 mm 
Hg) with both preservative-free tafluprost and 
BAK-preserved (0.1 mg/mL) tafluprost at the end 
of 1 week of therapy. The IOP lowering effect was 
maintained and was similar in both the groups at 
four weeks [30]. Kanamoto et al. performed a pro-
spective randomized crossover trial evaluating BAK 
toxicity. Authors compared tafluprost with 0.001% 
BAK, and travoprost preserved with SofZia. There 
was no significant difference in IOP lowering in 
the two groups [34]. Rouland et al. compared the 
IOP reducing efficacy and safety of preservative-free 
latanoprost to BAK-preserved latanoprost in a pro-
spective randomized trial. In the study, patients 
who previously instilled BAK-preserved latanoprost 
were randomized into two groups after a wash-out 
period. One group received preservative-free latano-
prost, while the other group received BAK-preserved 
latanoprost. Over 84 days, the mean IOP reduction 
was similar in the two groups (similar efficacy), while 
local tolerance was better with the preservative-free 
formulation [35]. Goldberg et al. compared the ef-
ficacy of bimatoprost/timolol preservative-free with 
BAK-preserved bimatoprost/timolol. They reported 
the preservative-free formulation to be non-inferior 
to the preserved formulation in terms of IOP lower-
ing from baseline at 12 weeks [28].
preservatives and oCuLar fLora
Ohtani et al. have investigated the impact of 
long-term administration of BAK-preserved latano-
prost (0.005%) eye drops and SofZia-preserved 
travoprost (0.004%) eye drops as monotherapy. Pa-
tients who were instilling the two drops for > 1 year 
were enrolled in this study. Their conjunctival 
scrapings were collected as a specimen and were 
cultured for isolating bacterial isolates. The authors 
also tested for the isolates’ drug susceptibility by 
measuring the minimum inhibitory concentrations 
(MIC50 and MIC90) of antibiotics (levofloxacin, 
gatifloxacin, moxifloxacin, cefmenoxime, ceftazi-
dime, tobramycin, chloramphenicol, and erythro-
mycin) as target antimicrobial agents against the 
obtained isolates. The authors reported that the 
frequency of isolation of MRSE (methicillin-re-
sistant Staphylococcus aureus) was significantly higher 
in patients instilling BAK-preserved latanoprost. 
In contrast, the patients on SofZia-preserved tra-
voprost and healthy controls did not. The authors 
also found that the MIC50 and MIC90 values for 
levofloxacin, gatifloxacin, moxifloxacin, cefmenox-
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ime, tobramycin, and erythromycin against the S. 
epidermidis isolates from the patients on BAK-pre-
served latanoprost were significantly higher than 
those against isolates from the patients on BAK-free 
travoprost. The authors also reported that the oc-
currence of multiple antibiotic-resistant S. epider-
midis (resistant against more than three antibiotics 
among: one or more of levofloxacin, gatifloxacin, 
and moxifloxacin, one or more of ceftazidime and 
cefmenoxime, tobramycin, chloramphenicol, and 
erythromycin) was significantly higher in the pa-
tients using BAK-containing latanoprost compared 
to the patients on BAK-free travoprost and healthy 
volunteers. The authors concluded that the indig-
enous conjunctival flora might be influenced by an 
increase in MRSE by the long-term use of prostag-
landin analogues [36].
Honda et al. studied the effects of chronic use 
(≥ 1 year) of anti-glaucoma drops on conjuncti-
val bacterial flora. An interesting outcome reported 
by the authors was that the culture positive rate 
was significantly lower in the patients instilling eye 
drops as compared to controls who were not on any 
eye drops [37]. Contrary to this, the culture positive 
rate was higher in patients with glaucoma than in 
healthy folks in another similar study by Sen et al. 
[38]. The reason for this disparity is likely owing to 
the difference in follow-up periods [37].
preservatives and anterior ChamBer
anterior chamber flare
Kestelyn et al. reported a statistically significant 
drop in anterior chamber flare just one month 
after switching from BAK-containing latanoprost 
to preservative-free latanoprost. The flare value de-
creased further after two months and after three 
months [39]. In a previous study by the same au-
thors (Kestelyn et al.), patients were randomly as-
signed to either BAK-preserved timolol or pre-
servative-free timolol after recording baseline AC 
flare values. After a 1-month follow-up, AC flare 
values were measured again. There was an increase 
in AC flare in both groups, but the increase in 
the BAK-preserved timolol group was more sig-
nificant than in the preservative-free group [40]. 
Abe et al. conducted a randomized study in which 
pseudophakic patients were randomized to either 
BAK-preserved artificial tears or preservative-free 
artificial tears four times a day for 30 days after 
baseline AC flare values and macular thickness-
es were recorded. After 30 days of follow-up, the 
BAK-preserved group showed a statistically signifi-
cant increase in mean AC flare values compared to 
baseline. The preservative-free group did not show 
a significant increase from baseline values. How-
ever, the authors did not note any significant in-
crease in macular thickness in either group. The 
authors concluded that short-term BAK exposure 
causes disruption of blood-aqueous barriers but not 
blood-retinal barriers in pseudophakic eyes [41].
trabecular meshwork
In an in vitro study by Samples et al., BAK 
inhibited trabecular meshwork cells’ growth, and 
these cells were also susceptible to BAK [42]. 
According to Hamard et al., unpreserved beta-block-
ers have no pro-apoptotic effect on human trabec-
ular meshwork cells. However, BAK-containing 
beta-blockers increased one pro-apoptotic marker, 
while treatment with pure BAK caused 95% of the 
cells to undergo apoptosis. The authors inferred that 
while BAK-preserved beta-blockers and prostaglan-
din analogues marginally increased only one out of 
three pro-apoptotic markers. The pro-apoptotic ef-
fect observed with pure BAK was inhibited by other 
active compounds present in the preserved topical 
eye drop formulation [43].  BAK had been detected 
in trabecular meshwork and iris by time-of-flight 
secondary ion mass spectroscopy and chromatogra-
phy coupled with mass spectrography [44].
Lens
In the Blue Mountains Eye Study, anti-glaucoma 
medications have increased the odds, albeit insig-
nificant statistically, for nuclear cataracts [45]. It has 
been suggested that chronic BAK exposure induces 
cell stress to the lens epithelium cells and induce 
cataract [46].
BaK and post-operative 
infLammation
According to several studies, BAK itself is more 
responsible than the active drugs (i.e. latanoprost 
or timolol) in anti-glaucoma drops for inducing 
early post-operative inflammation caused by dis-
rupting the blood-aqueous barrier [46–48]. Goto 
et al. reported that PGE2 expression is increased by 
latanoprost and timolol, especially in the presence 
of BAK. The authors suggested that BAK, by induc-
ing prostaglandins, causes post-operative cystoids 
macular edema after cataract surgery or glaucoma 
surgery [46].
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BaK and traBeCuLeCtomy faiLure
The Preservative Exposure and Surgical Out-
come Study (PESO study) retrospectively reviewed 
128 glaucoma patients who undergone trab-
eculectomy and been treated with anti-glaucoma 
medication(s) preoperatively for variable peri-
ods. The authors found that the time to surgical 
failure was shorter in patients preoperatively re-
ceiving higher daily doses of BAK as a preservative 
of their anti-glaucoma eye drops than in patients 
receiving lower BAK doses. It was clearly evident 
that preoperative exposure to BAK is a risk factor 
for early trabeculectomy failure [49]. However, con-
trary to the PESO study results, in another study, 
215 eyes that underwent trabeculectomy surgery 
were reviewed retrospectively. The authors did not 
find any significant negative effect of the preop-
eratively used anti-glaucoma drugs on the outcome 
of trabeculectomy [50]. Broadway et al. stopped 
sympathomimetic drops 30 days before filtration 
surgery in glaucoma patients and started them on 
fluorometholone 1% four times a day. The authors 
reported a decrease in fibroblasts and inflammatory 
cells in the conjunctiva [51]. Thus, it is suggestive 
that topical drugs induce inflammatory changes and 
have fibrosis-inducing effects that may influence the 
outcome of trabeculectomy. This inflammatory ef-
fect is most likely exerted by the preservative BAK 
present in topical anti-glaucoma medications [52].
ConCLusion
Benzalkonium chloride (BAK) has many adverse 
effects on the ocular surface, including tear film 
stability, conjunctiva, and cornea. Also, long-term 
effects include a possible decrease in susceptibility of 
ocular bacterial flora to commonly used antibiotics 
and an increase in the incidence of Methicillin-re-
sistant strains. Chronic exposure to BAK has been 
linked to an increased risk of trabeculectomy fail-
ure. Whether BAK-preserved drops are associated 
with more discomforting symptoms than preserv-
ative-free formulations is a matter of debate given 
the number of contradictory studies. Nevertheless, 
a good number of studies have pointed towards 
more discomfort and redness with BAK-preserved 
formulations. Keeping these facts in mind, preserv-
ative-free formulations or BAK-free formulations 
may be preferred over BAK-preserved ones while 
prescribing, especially anti-glaucoma medications, 
as these medications need to be instilled for long pe-
riods if not life-long. With more and more pharma-
ceutical companies shifting to preparing BAK-free 
formulations, a paradigm shift is imminent. Oph-
thalmologists, on the other hand, must pave the 
way for the same by choosing to prescribe BAK-free 
formulations whenever possible.
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